Furegrelate
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent.
For research use only. We do not sell to patients.
- CAS No.: 85666-24-6
- Formula: C15H11NO3
- Molecular Weight:253.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Furegrelate (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1].
Furegrelate blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2].
Furegrelate has a long half-life compared to several other drugs used to treat PAH, including nitric oxide and prostagcyclin analogues; And Furegrelate is highly specific to the target enzyme[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 85666-24-6
-
Molecular Weight 253.25
-
Formula C15H11NO3
-
SMILES
O=C(C1=CC2=CC(CC3=CC=CN=C3)=CC=C2O1)O
-
Synonyms
U-63557A free acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42. [Content Brief]
[2]. Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)